Kura Oncology, Inc.
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- 2 insiders sold shares within a monthSince Sep 28, 2026+6.4
Trials
- KURAKura Oncology, Inc.16Calm
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
FinishedPhase 1/245 patientsMain results: Aug 29, 2025 - KURAKura Oncology, Inc.6Calm
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Signing up patientsPhase 31,300 patientsMain results: Nov 2031 - KURAKura Oncology, Inc.6Calm
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
Running, no new patientsPhase 1/2263 patientsMain results: Oct 16, 2028
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
17 sales (2 not pre-planned) · 2 purchases
- FORD KATHLEENChief Operating Officer · Sep 29, 2026Sold 3,668 sharesabout $39 thousand · pre-planned
- Leoni MollieChief Medical Officer · Sep 29, 2026Sold 28,802 sharesabout $310 thousand · pre-planned
- Powl Brian T.Chief Commercial Officer · Sep 29, 2026Sold 15,430 sharesabout $166 thousand · pre-planned
- Bair Teresa BrophyChief Legal Officer · Sep 28, 2026Sold 8,442 sharesabout $89 thousand · pre-planned
- FORD KATHLEENChief Operating Officer · Sep 28, 2026Sold 6,906 sharesabout $72 thousand · pre-planned
- Leoni MollieChief Medical Officer · Sep 28, 2026
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.